LIPCAR |
Maladaptive remodelling (human) |
Supposed mitochondrial pathways regulation |
Plasma |
[80,81] |
WISPER |
Fibrosis and maladaptive remodelling (mouse, human) |
Super-enhancer for genes involved in fibrosis |
Myocardial biopsy |
[83] |
CHAST |
Cardiac remodelling (TAC in mouse and human AoS) |
Regulation of autophagy and hypertrophy |
Myocardial biopsy |
[84] |
CHAER |
Cardiac remodelling (TAC in mouse), dilated cardiomyopathy (human) |
Epigenetic reprogramming by interacting with polycomb repressor complex 2 |
Myocardial biopsy |
[85] |
ANRIL |
Inflammation, cardiac remodelling (mouse, human) |
NF-kB pathway and epigenetic reprogramming |
Myocardial biopsy |
[86,87] |
MALAT1 |
Diabetic cardiomyopathy, inflammation (mouse, human) |
Epigenetic control of inflammation |
Myocardial biopsy |
[88,89] |
MIAT |
Diabetic cardiomyopathy, inflammation (human) |
Promoting cardiac fibrosis by IL-17 production |
Serum |
[89,90] |
SENCR |
Diabetic cardiomyopathy (human) |
Control of smooth muscle cell phenotype |
Serum |
[89] |
HEAT2 |
Cardiac remodelling and fibrosis (human, mouse) |
Histone metilation |
Serum |
[91,92] |
MHRT |
Cardiac remodelling, hypertrophy (mouse, human) |
Chromatin remodelling by helicase BRG1 inhibition |
Plasma |
[93,95,96] |
NRON |
Cardiac remodelling (mouse) |
Regulation of NFAT and Calcium pathway |
Plasma |
[93,94] |
GASL1 |
Cardiac remodelling (mouse) |
Cardiomyocyte apoptosis modulation by TGF-b pathway |
Plasma |
[98] |
HOTAIR |
Inflammation, apoptosis (human, mouse) |
Modulation of NF-κB pathway |
Myocardial biopsy |
[84,92] |